Fourpath Capital Management LLC Sells 187 Shares of Danaher Co. (NYSE:DHR)

Fourpath Capital Management LLC reduced its holdings in shares of Danaher Co. (NYSE:DHR) by 1.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 13,327 shares of the conglomerate’s stock after selling 187 shares during the quarter. Fourpath Capital Management LLC’s holdings in Danaher were worth $3,059,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Fort Pitt Capital Group LLC grew its holdings in shares of Danaher by 3.2% during the 3rd quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate’s stock valued at $66,194,000 after purchasing an additional 7,421 shares during the last quarter. Good Life Advisors LLC acquired a new position in shares of Danaher during the third quarter worth $217,000. ORG Partners LLC increased its holdings in shares of Danaher by 1,212.8% during the fourth quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock worth $636,000 after buying an additional 2,559 shares in the last quarter. Harvest Portfolios Group Inc. boosted its holdings in shares of Danaher by 1.2% during the 3rd quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate’s stock valued at $56,233,000 after acquiring an additional 2,465 shares in the last quarter. Finally, Stifel Financial Corp boosted its holdings in shares of Danaher by 1.3% during the 3rd quarter. Stifel Financial Corp now owns 847,348 shares of the conglomerate’s stock valued at $235,583,000 after acquiring an additional 11,216 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Trading Down 3.9 %

Shares of Danaher stock opened at $214.09 on Tuesday. The firm has a market cap of $154.64 billion, a PE ratio of 40.55, a P/E/G ratio of 2.80 and a beta of 0.83. The stock has a fifty day moving average price of $235.40 and a 200-day moving average price of $253.09. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. Danaher Co. has a 1 year low of $214.03 and a 1 year high of $281.70.

Danaher (NYSE:DHR) last released its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period in the prior year, the company earned $2.09 earnings per share. Equities research analysts anticipate that Danaher Co. will post 7.77 EPS for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were given a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.50%. Danaher’s dividend payout ratio is currently 20.45%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Wells Fargo & Company cut their price target on Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 30th. Royal Bank of Canada restated an “outperform” rating and set a $277.00 price objective (down from $299.00) on shares of Danaher in a research report on Thursday, January 30th. Jefferies Financial Group decreased their price target on Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a report on Wednesday, January 29th. JPMorgan Chase & Co. dropped their target price on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Finally, Robert W. Baird cut their price objective on shares of Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Seven equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $278.00.

Insiders Place Their Bets

In related news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 10.90% of the stock is owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.